{"disease":{"id":"alk-positive","name":"alk positive"},"drugs":{"marketed":[{"drug_id":"lorbrena","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"Lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"1100","mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) with brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"ALK-positive metastatic NSCLC without brain metastases","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"ALK-positive metastatic NSCLC with brain metastases and with or without echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"brigatinib","indication_name":"Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alunbrig","generic_name":"brigatinib","company_name":"Takeda","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells."},{"drug_id":"lorviqua","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"ceritinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zykadia","generic_name":"ceritinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zykadia blocks the activity of the ALK protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"lorlatinib","indication_name":"ALK fusion gene-positive non-small-cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorbrena","generic_name":"lorlatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Lorbrena works by blocking the activity of the ALK tyrosine kinase receptor, which is a protein that helps cancer cells grow."}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04647110","title":"Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.","phase":"","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01970865","title":"A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":364,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03727477","title":"Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib","phase":"","overall_status":"COMPLETED","enrollment_count":291,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT06569420","title":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","has_results":false},{"nct_id":"NCT04009317","title":"Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":260,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT02584933","title":"Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":233,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06846736","title":"ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT06361589","title":"Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT05132218","title":"Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT02201992","title":"Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT07491497","title":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"TRIANA Biomedicines, Inc.","has_results":false},{"nct_id":"NCT02336451","title":"A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04042558","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT04058470","title":"Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT01979536","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04056572","title":"Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":135,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06092086","title":"Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT03410108","title":"Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03535740","title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Ariad Pharmaceuticals","has_results":true},{"nct_id":"NCT06904547","title":"Resistance Mechanisms and Sequential Treatment Strategies Following First-Line Lorlatinib in ALK-Positive NSCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT05122806","title":"Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Groupe Francais De Pneumo-Cancerologie","has_results":false},{"nct_id":"NCT06736561","title":"A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Harbin Medical University","has_results":false},{"nct_id":"NCT06176690","title":"Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT05934045","title":"Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03493451","title":"Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04499794","title":"The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring","phase":"","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04900935","title":"Patient-centered, Optimal Integration of Survivorship and Palliative Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02393625","title":"Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04231877","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03038672","title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02561273","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT04979988","title":"Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients","phase":"","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04087473","title":"Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT03113500","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04774718","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03672643","title":"Long Term Safety Observation of Crizotinib in Chinese NSCLC Population","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03779191","title":"Alectinib in Combination With Bevacizumab in ALK Positive NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Instituto Nacional de Cancerologia de Mexico","has_results":false},{"nct_id":"NCT06834373","title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03603847","title":"Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT07122882","title":"Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05178511","title":"Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Li Zhang, MD","has_results":false},{"nct_id":"NCT07140016","title":"A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02227940","title":"Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02321501","title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04476459","title":"Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":33,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT02422589","title":"A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04796857","title":"Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Huiqiang Huang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}